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Aim: To investigate the role of 18F–NaF PET/CT and compare it with 99m Tc-MDP whole body bone
scintigraphy and 18F-FDG PET/CT in detecting the extent of metastatic bone disease and to present our
ﬁrst experience with 18F–NaF PET/CT in our country.
Materials and methods: A total of 37 histopathologically proven cancer patients (22 male, 15 female) with
bone metastasis detected on Tc-99m MDP whole body bone scan were prospectively enrolled Cebeci,
following ethics committee approval. 18F–NaF PET/CT was performed to the participants in Ankara
University Medical Faculty Nuclear Medicine Department for evaluation of symptomatic skeletal sites
which were negative on Tc-99m MDP whole body bone scan. A lesion based comparison was made
between 18F–NaF PET/CT and Tc-99m MDP whole body bone scan for each patient and between 18F–NaF
PET/CT and 18F-FDG PET/CT in 12/37 patients.
Results: The number of lesions demonstrated by 99m Tc-MDP bone scan and 18F–NaF PET/CT was equal
in 4/37 (%11) of the cases. 18F–NaF PET/CT showed a greater number of pathological foci in 89% of
participants. 18F–NaF PET/CT was able to show both lytic and blastic lesions and small lesions were
better visualized due to the advantage of sectional imaging with much better resolution and higher
target/background ratio. 18F–NaF PET/CT demonstrated a greater number of metastases in 10/12 (83%) of
the patients when compared to 18F-FDG PET/CT. In the other two patients, bone metastasis could be
demonstrated only by 18F–NaF PET/CT. The uptake of 18F-FDG was variable in blastic lesions and cranial
bone involvement was missed by 18F-FDG PET/CT in some cases due to physiological brain metabolism.
Conclusion: Although further prospective clinical studies in speciﬁc cancer populations are indicated to
set the place of 18F–NaF PET/CT in diagnostic scheme, the results of this pilot study from our country
support the superiority of 18F–NaF PET/CT in investigation of bone metastasis over 99mTc-MDP bone
scan and 18F-FDG PET/CT in various malignancies. 18F–NaF PET/CT is coming forward as a single step
bone seeking study, considering all the advantages, but especially potential of detecting occult metas-
tases and reliably directing patient management.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Metastatic bone disease is the most frequent malignancy of the
skeletal system [1]. Early diagnosis of bone metastases is an im-
portant step in the management of cancer as they may cause
serious endocrinologic, hematologic, neurologic and orthopedic
complications and intolerable pain [2,3].
The most common method for bone scanning is Technetium-
99m methylenediphosphonate (99mTc- MDP) bone scintigraphy,
because 99mTc- MDP is a cheap and easily available radio-
pharmaceutical with no toxic effects and whole body bone scin-
tigraphy has an acceptable sensitivity, speciﬁcity, positive and
negative predictive value.GmbH. This is an open access artFluorine 18-Fluorodeoxyglucose positron emission tomography/
computerized tomography (18F-FDG PET/CT) is now used as a
useful imaging tool for staging, restaging and evaluation of therapy
response for most cancers. The uptake mechanism of the radio-
pharmaceutical in bone metastases depends on the pathological
increase in glycolytic activity of the malignant cells, therefore 18F-
FDG shows speciﬁcally the malignancy of the bone. 18F-FDG PET/CT
also contributes to the true evaluation of bone marrow involvement
and soft tissue component of the metastasis [4].
Fluorine 18–Sodium Fluoride (18F–NaF) has been introduced as
a bone-seeking agent ﬁrst in 1962 by Blau et al. [5] and approved
by FDA in 1972 for detection of osteogenic activity. However it lost
its popularity by the easy availability of Molibdenum-99 (Mo-99)
generators and better imaging characteristics of 99mTc- for gam-
ma cameras, with respect to the high energy photons of Fluorine-
18. As PET technology spread all around the world in 1990's, 18F–icle under the CC BY-NC-ND license
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the radiopharmaceutical is quite useful for imaging. After in-
travenous injection, it is cleared out from the blood pool fast and it
forms ﬂuoroapetite crystals by chemoadsorbtion to the hydro-
xyapatite crystals [7].
The aim of this study was to investigate the role of 18F–NaF
PET/CT and compare it with 99m Tc-MDP whole body bone scin-
tigraphy and 18F-FDG PET/CT in detecting the extent of metastatic
bone disease and to present the results of our ﬁrst experience with
18F–NaF PET/CT practice in our country.2. Materials-methods
2.1. Patient group
Ankara University Ethics Committee approval was taken for the
study. A total of 37 histopathologically proven cancer patients (22
male, 15 female) with bone metastasis detected on Tc-99m MDP
whole body bone scan were prospectively enrolled. 18F–NaF PET/
CT was performed to the participants in Ankara University Medical
Faculty Nuclear Medicine Department for evaluation of sympto-
matic skeletal sites which were negative on Tc-99m MDP whole
body bone scan. Informed consent for 18F–NaF PET/CT procedureTable 1
Patient characteristics.
Patient Age Gender Primary pathology Therapy histo
1 64 F Hodgkin's Lymphoma Chemotherap
2 81 F Breast cancer Chemotherap
3 49 F Gastric cancer Chemotherap
4 80 M Prostate cancer No history of
5 46 F Breast cancer Chemotherap
radiotherapy
6 60 M Lung cancer Radiotherapy
7 52 M Lung cancer Radiotherapy
8 50 M Prostate cancer Chemotherap
radiotherapy
9 32 M Nasopahrynx cancer Chemotherap
10 36 M Renal cell carcinoma No history of
11 48 F Breast cancer No history of
12 77 F Lung cancer No history of
13 72 F Cervix cancer No history of
14 53 M Renal cell carcinomaþneuroendocrine tumor Radiotherapy
15 68 F Uterine leiomyosarcoma Radiotherapy
16 66 M Lung cancer No history of
17 80 M Urinary bladder cancer No history of
18 39 F Breast cancer Chemotherap
radiotherapy
19 55 M Lung cancer No history of
20 87 F Breast cancer No history of
21 34 F Breast cancer No history of
22 68 F Colon No history of
23 68 F NonHodgkin lymphoma No history of
24 46 M Colonþprostate cancer No history of
25 57 M Gastric cancer Radiotherapy
26 60 F Breast cancer Radiotherapy
27 45 F Breast cancer Radiotherapy
28 31 F Breast cancer Radiotherapy
29 64 M Prostate cancer No history of
30 37 M Lung cancer No history of
31 66 M Pancreas neuroendocrine tumor Radiotherapy
32 59 M Lung cancer Chemotherap
radiotherapy
33 78 M Prostate cancer Chemotherap
radiotherapy
34 79 M Prostate cancer Hormonother
35 66 M Prostateþ lung cancer Chemotherap
36 72 M Prostate cancer Radiotherapy
37 55 M Lung cancer Chemotherapwas signed by all participants. All patients were over 18 years old
with a mean age of 58.91. Also, the results of other imaging
modalities concurrently performed with bone scans and 18F–NaF
PET/CT for staging, restaging or evaluation of therapy response
were also taken under consideration. Twelve patients (32%) also
had 18F-FDG PET/CT and 2 patients (0.5%) had In-111 Octreotide
whole body scintigraphy and 1 patient had Ga-68 DOTATATE PET/
CT. There were 9 breast, 8 lung, 6 prostate, 2 gastric cancer, 1 na-
sopharynx, 1 cervix, 1 bladder, 1 colon cancer, 1 renal cell carci-
noma (RCC), 1 RCC and neuroendocrine tumor (NET), 1 colon and
prostate, 1 lung and prostate cancer, 1 pancreas NET, 1 Hodgkin's
Lymphoma (HL), 1 non-Hodgkin Lymphoma (NHL) and 1 uterine
leiomyosarcoma patients. Fifteen patients have not received any
chemo-radiotherapy yet while 10 received only radiotherapy,
6 received only chemotherapy, and 5 received both. One prostate
cancer patient received only hormonotherapy (Table 1).
2.2. 18F–NaF PET/CT protocol
No special patient preparation was needed except for oral hy-
dration, so that fast clearance from the background and a lower
whole body radiation exposure could be obtained. The history of
the disease, the chemotherapy, radiotherapy and antihormonal
therapy performed were noted for evaluation. The injected dosesry 18F–NaF
PET/CT
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ging. PET scanning started 30 min after injection in supine position
from vertex to the midthigh with 3 min/bed position and lower
extremities were scanned at about 45 min after injection. CT
images from vertex to the toes were obtained for attenuation
correction and localization. Low dose CT acquisition was per-
formed with 140 kV, 70 mA, 0.5 s per CT rotation, a pitch of 6 and a
section thickness of 5 mm. (Discovery ST PET/CT scanner, General
Electric, Milwaukee, Wisconsin, USA was used.)
2.3. 18F–NaF PET/CT image interpretation
Two nuclear medicine specialists made a visual analysis and a
consensus was reached in order to avoid inter-observer variability.
The readers were blind to the clinical data and to the results of
other examinations. First, Maximum intensity projection (MIP)
and then sectional images were examined for interpretation. Areas
of higher or lower 18F–NaF uptake with respect to the neighboring
or symmetrical bone tissue were recorded as pathological and
evaluation for metastasis was done by the radiological character-
istics of the lesions obtained from the CT data. If changes referring
to a benign etiology was detected on CT images overlapping the
pathological 18F–NaF uptake, then this uptake was not interpreted
as metastatic (for example, activities corresponding to facet joints,
vertebra endplates, osteophytes, large joints of the extremities,
traumatic fractures etc.).
2.4. Data analysis
A lesion based analysis was made. The pathological uptake sites
recorded on both Tc-99m MDP bone scan and 18F–NaF PET/CT
scans were directly compared for each patient. For the 12 patients
with 18F-FDG PET/CT, 2 patients with In-111 octreotide scinti-
graphy and 1 patient with Ga-68 DOTATATE PET/CT, similar lesion
based comparison was also made between 18F–NaF PET/CT images
and other examinations listed. The detectability of Tc-99m MDP,
18F–NaF and 18F-FDG radiopharmaceuticals according to theFig. 1. Demonstration of a greater number of lesions in 18F–NaF PET/CT (b) study tha
Lymphoma.nature of the metastases, either osteoblastic or osteolytic were also
taken in consideration by the help of the radiological data pro-
vided by the CT component of the PET/CT images.3. Results
All 99mTc- MDP bone scintigraphy and 18F–NaF PET/CT results
were positive for bone metastasis while 18F-FDG PET/CT results
were negative in some of the cases. The results were analyzed
with one to one comparison of the examinations for every patient.
3.1. Comparison between 18F–NaF PET/CT and 99mTc- MDP whole
body scintigraphy
In the comparison results of 18F–NaF PET/CT and 99mTc- MDP
whole body scintigraphy of the patients, the number of lesions
demonstrated by both examinations was equal in 4/37 (11%) cases
and 18F–NaF PET/CT showed multiple pathological foci in 33/37
(89%). This was attributed to the facts that 18F–NaF PET/CT could
show both lytic and blastic lesions and small lesions are better
visualized with high resolution and high target/background ratio
(Fig. 1a and b).
The sectional images provided by 18F–NaF PET/CT was ad-
vantageous over planar bone scintigraphy in the way that some
lesions that could not be recognized or localized by 99mTc-MDP
bone scan were easily detected by PET. (Figs. 2a and b, 3a and b).
3.2. Comparison between 18F–NaF PET/CT and 18F-FDG PET/CT
The comparison results of 18F–NaF PET/CT and 18F-FDG PET/CT
revealed that 18F–NaF PET/CT demonstrated a greater number of
metastases in 10/12 (83%) patients. 18F-FDG PET/CT was unable to
demonstrate bone metastasis in the other two cases (HL and cer-
vix carcinoma).
18F–NaF PET/CT could show both blastic and sclerotic lesions
(Figs. 4a and b, 5a and b). 18F–NaF PET/CT was commonly moren 99mTc- MDP whole body bone scintigraphy (a) in a patient with Non-Hodgkin
Fig. 2. In the RCC patient, the lesion cannot be distinguished from bladder activity
in 99mTc- whole body bone scintigraphy (a) while it can be demonstrated on axial
images of the pelvis on 18F–NaF PET/CT (b).
Fig. 3. Demonstration of the uptake seen in the nasal region on 18F–NaF PET/CT
MIP images (a) belonging to sphenoid bone metastases on axial images (b) in a
metastatic colon cancer patient.
Fig. 4. Axial CT image of sclerotic metastastases on the 6. left costa (a) and intense
pathological 18F–NaF uptake (b).
Fig. 5. Axial CT image of a lytic metastatic lesion of the cranium (a) with intense
pathological 18F–NaF uptake (b).
Fig. 6. Cranial bone involvement cannot be distinguished on 18F-FDG PET/CT axial
sections (a) due to the physiological brain metabolism, but it is demonstrated well
on 18F–NaF PET/CT axial images (b).
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Additionally, 18F–NaF PET/CT could easily detect cranial bone
involvement that 18F-FDG PET/CT missed because physiological
brain metabolism masked (Fig. 6a and b).
Bone marrow involvement could not be demonstrated in the
99mTc MDP bone scans but was positive in 5 patients (13%) in
18F–NaF PET/CT (Fig. 7a and b).Fig. 7. Demonstration of focal 18F–NaF uptake sites seen on 18F–NaF PET/CT MIP
images (a) at the distal femur bilaterally belonging to bone marrow involvement on
axial sections (b).
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be demonstrated on 18F-FDG PET/CT, 15 lesions were seen on bone
scan and countless, extensive metastases throughout the skeleton
were detected on 18F–NaF PET/CT.
The HL patient had no skeletal involvement on 18F-FDG PET/CT,
only a heterogeneous nonspeciﬁc uptake in the vertebral column
on bone scan was detected but marked 18F–NaF uptake around
the lytic lesions were identiﬁed on CT images of the lumbar ver-
tebrae. Similarly, in the cervix carcinoma patient, while there were
no metastatic lesions on 18F-FDG PET/CT, multiple pathological
foci were detected by 99mTc- MDP whole body bone scintigraphy
and 18F–NaF PET/CT.
In NHL and nasopharynx cancer patients, ﬁndings were com-
patible in both three modalities showing extensive skeletal
metastases.
3.3. Comparison between 18F–NaF PET/CT and other modalities in
NET patients
The pancreas NET case showed 6 bone metastases on In-111
octreotide scintigraphy, 15 lesions on Ga-68 DOTA-Tyr3-Octreotate
(DOTATATE) PET/CT and 19 lesions on 18F–NaF PET/CT.4. Discussion
The aim of this study was to evaluate the role of 18F–NaF PET/
CT in detecting the extent of metastatic bone disease in compar-
ison with 99mTc- MDP whole body bone scintigraphy and 18F-
FDG PET/CT and to present our ﬁrst experience with 18F–NaF.
Since 1990's, when PET/CT cameras started to gain prevalence
around the world, the studies published about the utility of 18F–
NaF PET/CT in metastatic bone disease were carried on speciﬁc
patient groups like prostate, breast, thyroid and hepatocellular
cancer. Although the diversity of primary diagnosis of the patients
in our patient group interrupts homogeneity, a vast majority of our
patients (62%) have the most commonly studied cancer types
(prostate, breast and lung cancer).
The general statement that can be concluded from the studies
comparing the utility of 18F–NaF PET or PET/CT with 99mTc- MDP
whole body bone scintigraphy is that 18F–NaF PET/CT generally
has a higher sensitivity and speciﬁcity than bone scan. Higher
uptake of 18F–NaF than 99mTc- MDP in the skeleton and a faster
blood clearance, yield a better target/background ratio in a shorter
time period. 18F–NaF uptake in both lytic and blastic metastasis,
sectional imaging advantage of the whole body and easy detection
of small lesions with improved resolution of PET technology,
better visualization of bone marrow lesions are all contributing
factors to the success of 18F–NaF PET/CT [7–16]. This is important
in the way that 18F–NaF PET/CT may diagnose metastatic lesions
while other modalities are found normal and thus alter the stage
and management of the cancer patients. In our study, compatibly
with the literature data, we observed 18F–NaF uptake in both lytic
and blastic metastases. Small lesions, which could not be detected
by 99mTc- MDP whole body bone scintigraphy, were easily vi-
sualized by the high-resolution power of PET/CT in 18F–NaF PET/
CT studies. Although no bone marrow involvement could be de-
monstrated on 99mTc- MDP whole body bone scintigraphy, in
some patients 18F–NaF showed an ability of true distinguishing of
marrow lesions especially when focal uptake sites are close the
joints where high uptake can be seen due to degenerative process.
In studies comparing 18F–NaF PET/CT with 99mTc- MDP whole
body bone scan and SPECT, although no statistically signiﬁcant
difference between the accuracy of SPECT and 18F–NaF PET was
found, the investigators argued that 18F–NaF PET was still the best
imaging tool for bone scanning since SPECT imaging of the entirevertebral column took quite a long time [14,17]. SPECT was beyond
the scope of our study, but if could be performed, some other le-
sions, like the one missed in 99mTc- MDP whole body bone
scintigraphy in the symphysis pubis due to bladder activity and
the sphenoid bone metastasis which could not be differentiated in
the anterior view of the MIP images, would possibly be detected
also by bone scintigraphy on SPECT images.
There are only a few studies directly comparing the effective-
ness of 18F-FDG PET/CT and 18F–NaF PET/CT in the literature. Al-
though the method of choice is 18F-FDG PET/CT for bone imaging
in malignancies, which commonly present lytic bone metastases, it
has been reported that the diagnostic accuracy of 18F–NaF PET/CT
is higher than 18F-FDG PET/CT in various cancers [18–25]. In our
study, 18F-FDG PET/CT and 18F–NaF PET/CT could be compared in
12 patients. 18F–NaF PET/CT showed a greater number of lesions in
10/12 patients. 18F-FDG PET/CT was negative for bone metastasis
in the other 2 cases.
The uptake of 18F-FDG in metastatic bone disease depends on
the glycolytic activity of the tumoral bone lesions. Although it
seems to be tumor speciﬁc, 18F-FDG has a limited sensitivity in
detection of low-grade tumors growing slowly and have low gly-
colytic activity [22,23].
One reason for detecting a greater number of lesions in 18F–
NaF PET/CT in our study was th at cranial bone involvement could
be demonstrated by 18F–NaF PET/CT. In some of these cases, the
physiological brain metabolism masked the possible uptake of
18F-FDG in the cranial bones. In the literature, there were no
comments on these distinctive characteristics of these two
radiopharmaceuticals.
The types of the primary tumor of 12 patients who have also
undergone 18F-FDG PET/CT were heterogeneous (2 breast, 4 lung,
1 nasopharynx, 1 cervix cancer, 1 RCC, 1 HL, 1 NHL and 1 uterine
leiomyosarcoma). There exists a case report showing the effec-
tiveness of 18F–NaF PET/CT in RCC [26]. In our series, while there
were only two bone lesions on 18F-FDG PET/CT of the RCC patient,
18F–NaF PET/CT revealed extensive skeletal metastasis. There are
no studies speciﬁcally investigating the role of 18F–NaF PET/CT in
lymphoma, nasopharynx cancer, NET or gynecological tumors. We
demonstrated that in these cases 18F–NaF PET/CT was superior to
99mTc-MDP bone scan, 18F-FDG PET/CT and to Ga-68 DOTATATE
PET/CT in NET. Although the number of patients is limited, our
pilot ﬁndings may still contribute to the literature.
This was a prospective pilot study performed in our depart-
ment in order to examine the role of 18F–NaF PET/CT by com-
paring the results of 18F–NaF PET/CT primarily with Tc-99m MDP
bone scan and 18F-FDG PET/CT, the two imaging modalities fre-
quently used to assess skeletal involvement in oncology. To the
best of our knowledge, our results also reﬂect the ﬁrst experience
of 18F–NaF PET/CT practice in our country. There were some
limitations of this study including the heterogeneity of the study
population in terms of diagnosis and received therapies, bias to-
wards patients with known bone metastasis, unavailability of
SPECT imaging and impossibility of histopathological conﬁrmation
of pathological sites due to ethical concerns. Further prospective
studies are needed in speciﬁc malignancies in order to demon-
strate the clinical beneﬁts of 18F–NaF PET/CT over other imaging
tools.5. Conclusion
Our pilot study supports the superiority of 18F–NaF PET/CT
over Tc-99m MDP bone scintigraphy and 18F-FDG PET/CT. It has a
potential to replace them both as a bone seeking study, con-
sidering all the advantages and ability of detecting occult bone
metastasis and therefore directing the staging of the patients, but
M. Araz et al. / Journal of Bone Oncology 4 (2015) 92–97 97further prospective studies should be enrolled to set the role and
usage of 18F–NaF PET/CT in routine clinical practice.Acknowledgments
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